GLP-1 and Intestinal Diseases

Jenna Elizabeth Hunt, Jens Juul Holst, Palle Bekker Jeppesen, Hannelouise Kissow

    31 Citationer (Scopus)

    Abstract

    Accumulating evidence implicates glucagon-like peptide-1 (GLP-1) to have, beyond glucose maintenance, a beneficial role in the gastrointestinal tract. Here, we review emerging data investigating GLP-1 as a novel treatment for intestinal diseases, including inflammatory bowel diseases, short-bowel syndrome, intestinal toxicities and coeliac disease. Possible beneficial mechanisms for these diseases include GLP-1's influence on gastric emptying, its anti-inflammatory properties and its intestinotrophic effect. The current knowledge basis derives from the available GLP-1 agonist treatments in experimental animals and small clinical trials. However, new novel strategies including dual GLP-1/GLP-2 agonists are also in development for the treatment of intestinal diseases.

    OriginalsprogEngelsk
    Artikelnummer383
    TidsskriftBiomedicines
    Vol/bind9
    Udgave nummer4
    Sider (fra-til)383
    ISSN2227-9059
    DOI
    StatusUdgivet - 5 apr. 2021

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'GLP-1 and Intestinal Diseases'. Sammen danner de et unikt fingeraftryk.

    Citationsformater